The adverse event profile of @entity4677 : A meta-analysis on XXXX and adults.

@entity1 @entity4677 @entity11266 @entity146 @entity29279 @entity1295 @entity1395 @entity2147
PURPOSE: To analyze the adverse events (AEs) significantly associated with @entity4677 ( @entity29279 ) therapy through a meta-analysis of all available double-blind, randomized placebo-controlled trials (RCTs), performed in any age, gender, ethnic background and disease. General tolerability and study withdrawals due to AEs associated with @entity29279 treatment were also investigated. In addition, a dose-effect responses relationship for all variables was assessed. METHODS: RCTs were identified searching Medline (PubMed), Embase and Cochrane CENTRAL for the words " @entity4677 " and "randomized controlled trial", with different search strategies, setting the limits " @entity1 " and "English". Very common and common AEs according to the summary of product characteristics were investigated. RevMan version 5.2 was used for the statistical analyses. Risk difference with 95% confidence intervals was used to investigate the association of any AEs and withdrawal with @entity29279 . RESULTS: Twenty-six studies with 2832 @entity1 were included in the RCTs analysis. @entity11266 , @entity2147 , dizziness, nervousness/ @entity146 and @entity1395 / @entity1295 were statistically significant associated with @entity29279 . In addition, @entity29279 was significantly associated with an increased risk of AEs-related withdrawals. No dose-response relationship was found for any of the assessed variables. CONCLUSIONS: This first large meta-analysis suggests that @entity1 were more likely to discontinue @entity29279 than placebo. The AE profile confirmed that @entity29279 is associated with few unfavorable sedative, vestibulocerebellar and behavioral effects, such as nervousness and @entity146 . However, there does not seem to be a clear dose-response relationship.
